Table of Contents
Coronary Artery Disease ................................................................. 2
  Who Is at Risk? ........................................................................ 3
  Diagnosis of Coronary Artery Disease ...................................... 3
Treatment of Coronary Artery Disease .......................................... 3
  Angioplasty ............................................................................ 4
  Coronary Artery Stents ............................................................ 4
  Restenosis .............................................................................. 5
Your Drug-Eluting Stent ................................................................. 7
  Drug-Eluting Stents ................................................................. 7
  The Express® Stent and Liberte® Stent Platforms for the TAXUS® Stent ........................................... 7
  The Polymer Coating on the TAXUS Stent ................................. 8
  The Drug That Is Released from the TAXUS Stent .................... 8
  When Should the TAXUS Stent NOT Be Used? ......................... 8
  What Are the Risks & Potential Benefits of Treatment with the TAXUS Stent? ............................... 9
Alternative Practices and Procedures ........................................... 11
The Angioplasty Procedure ........................................................... 12
  Preparation for the Procedure ............................................... 12
  Angioplasty and Stent Placement Procedure ......................... 12
Post-Treatment ............................................................................ 13
  After the Procedure .............................................................. 13
  Activity ................................................................................ 13
  Medications .......................................................................... 14
  Follow-Up Examinations ......................................................... 14
Frequently Asked Questions ......................................................... 15
Glossary ..................................................................................... 15
Coronary Artery Disease

Coronary Artery Disease (CAD) is usually caused by atherosclerosis, and affects the coronary arteries that surround the heart. These coronary arteries supply blood with oxygen and other nutrients to the heart muscle to make it function properly. CAD occurs when the inner walls of the coronary arteries thicken due to a buildup of cholesterol, fatty deposits, calcium and other elements. This material is known as plaque. As plaque develops, the artery narrows. When the artery narrows (for example with physical exertion or mental stress), blood flow through the artery is reduced so less oxygen and other nutrients reach the heart muscle. This reduced blood flow may cause mild to severe chest pain or chest pressure. This pain or pressure can also spread to the arms or jaw, a condition known as angina pectoris. Complete obstruction (no blood flow) of a coronary artery can result in a heart attack (myocardial infarction).

Anyone who experiences symptoms of angina pectoris or myocardial infarction should promptly seek medical care.

Over 13 million Americans suffer from CAD each year. However, treatment options for CAD have substantially improved in recent years, and many CAD patients are now able to return to a normal lifestyle shortly after treatment.
Who Is at Risk?
People with a history of high cholesterol, diabetes, smoking, high blood pressure, being overweight and a family history of CAD have an increased risk of developing atherosclerosis in the coronary arteries. Increasing age adds to the risk of CAD. In addition, menopausal status may play a role in women.

Diagnosis of Coronary Artery Disease
Doctors may use various tests to diagnose CAD. An electrocardiogram (ECG or EKG) measures your heart’s electrical activity and may show whether parts of your heart muscle have been damaged by a heart attack due to CAD. A stress test records your heart’s electrical activity while you are exercising and may tell your doctor whether part of your heart muscle is damaged. A coronary angiogram is a procedure performed by a cardiologist in a cardiac catheterization lab. This procedure is done by injecting a contrast dye into the coronary arteries so that the arteries can be seen on an X-ray screen. The angiogram will show if any blockages and/or artery narrowing has occurred. This will help your doctor decide how to treat you.

Treatment of Coronary Artery Disease
CAD may be managed through a combination of changes in lifestyle and physical activity, diet and medical treatment. The therapy your doctor recommends will depend on the condition and severity of the disease. Nitroglycerin is often given to relieve chest discomfort due to blockages, but does not treat the blockage itself. Medical treatments of the blockage may include medications, angioplasty, with or without stent placement, or coronary artery bypass graft surgery (CABG).
**Angioplasty**

Angioplasty is a minimally invasive treatment of the coronary arteries performed in the hospital to open blocked arteries, also known as percutaneous transluminal coronary angioplasty (PTCA). A thin tube known as a catheter is inserted through the groin or wrist and is then threaded through a major artery to the site of the blockage. A small balloon, located on the tip of the catheter, is then expanded to reduce the blockage. PTCA can be performed with a balloon alone, or can involve the placement of a coronary stent.

**Coronary Artery Stents**

Coronary artery stents are devices that can help to reduce the risk of recurrent blockage or narrowing following an angioplasty procedure. Stents are small expandable metal tubular structures (lattice) that are implanted into an artery and expanded to fit the size, shape and bend of the arterial wall, propping it open to help prevent further blockages. Once in place, the stent will remain in your artery. Over time, the artery wall will heal around the stent as it continues to support the artery.
**Restenosis**

Many patients who undergo *balloon angioplasty* treatment will experience a re-narrowing of the artery, or *restenosis*, in the area that was treated. The rate of restenosis within the first six months after the angioplasty procedure is between 30 and 50 percent for angioplasty patients who do not receive a stent. The re-narrowing can be caused by a combination of factors including vessel recoil and formation of tissue ingrowth in the treated area.

**Cross Section of Coronary Artery**

- **Coronary Artery Disease (Initial Artery Size with Typical Plaque)**
- **After Expansion by Balloon Angioplasty—Plaque Pushed Back, Artery Wall Stretches**
- **Vessel Recoil (Stretched Vessel Naturally Returns to Initial Size)**
- **Restenosis Narrows Treated Vessel Over Time (Initial Artery Size Plus Tissue Ingrowth)**
Although coronary artery stents have proven to reduce the occurrence of restenosis compared to balloon angioplasty, restenosis still occurs in approximately 10 to 30 percent of patients who receive bare metal stents. Unlike restenosis after balloon angioplasty, restenosis in a stent (*in-stent restenosis*) is not typically associated with *vessel recoil*. Instead, in-stent restenosis primarily results from increased tissue ingrowth.
Your Drug-Eluting Stent, the TAXUS® Paclitaxel-Eluting Coronary Stent Systems

**Drug-Eluting Stents**
A drug-eluting stent is a bare metal stent that has been coated with a drug and a polymer. Drug-eluting stents are designed to deliver a drug locally to reduce tissue ingrowth.

Cross section of a coated stent to point out how coating conforms to the surface of the bare metal stent

Note: A green color is used to show coating but actual coating is clear.
*Liberté® stent design shown

**TAXUS Paclitaxel-Eluting Coronary Stent Systems:**
- **TAXUS® Express² Paclitaxel-Eluting Coronary Stent System**
- **TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System**

Boston Scientific offers two stent platforms or designs: the TAXUS Express® Stent and the TAXUS Liberté Stent. The information in this guide generally applies to both stent platforms. Depending upon your specific needs, your physician may have chosen to place either the TAXUS Express Stent or TAXUS Liberté Stent. Both stents are designed to be very flexible, allowing them to conform to the natural curves of your artery.
The Polymer Coating on the TAXUS® Stent

The stent is coated with a proprietary polymer (a chemical compound) called Translute™, which was developed specifically for the TAXUS Stent. The Translute Polymer is also known as SIBS [poly(styrene-b-isobutylene-b-styrene)]. The polymer carries and protects the drug before and during the procedure. Then, once the stent is implanted in the coronary artery, it helps control drug release into the arterial wall. This contributes to even and consistent distribution of the drug from the stent.

The Drug That Is Released from the TAXUS Stent

The TAXUS Stent is coated with the drug paclitaxel and the polymer. The paclitaxel/polymer coating has been designed to allow for a consistent and controlled release of the drug from the stent surface into the artery walls, to minimize release into the bloodstream. Both the amount of drug and release rate have been determined so that healing can occur while allowing the processes leading to restenosis to be minimized, thus reducing the need for additional treatment in the stented area.

The TAXUS Stent uses a very small but effective dose of paclitaxel, which is released slowly over the time period when restenosis is most likely to occur. Some paclitaxel will remain on the stent, with no additional measurable amount being released into the body.

NOTE: Paclitaxel is also available in injection form, known by the trade name Taxol®, and is also available in generic formulations. Let your doctor know if you are currently using this drug.

When Should the TAXUS Stent NOT Be Used? (Contraindicated)

- If you have an allergy to the drug paclitaxel or structurally related drugs, the SIBS polymer or stainless steel.
- If you cannot take aspirin or blood-thinning medications (also called antiplatelets or anticoagulants).
- If the physician decides that the blockage will not allow complete inflation of the angioplasty balloon or proper placement of the stent.
What Are the Risks & Potential Benefits of Treatment with the TAXUS® Stent?

Potential adverse events which may be associated with the implantation of a coronary stent include:

- air, tissue or clots which can block the vessel (emboli)
- allergic reaction to the contrast dye (which could include kidney failure)
- allergic reaction to the metal used to make the stent (stainless steel)
- aneurysm
- bleeding that would require a blood transfusion
- bruising at the access site
- bruising which resides on a blood vessel (pseudo-aneurysm)
- chest pain or discomfort
- collection of blood in the lining of the heart
- coronary spasms
- death
- emergency bypass surgery
- heart attack
- high or low blood pressure
- inadequate supply of blood to the heart
- infection and/or pain at the access site
- injury or tearing of blood vessel
- irregular heartbeat (arrhythmia)
- movement of the stent as it is sliding from the balloon into the blood vessel (embolization)
- plugging of the stent with blood clots
- renewed formation of a narrowing in the treated vessel (restenosis)
- side effects due to contrast dye or heparin
- shock/pulmonary edema
- stroke or other neurological events
- total occlusion of the vessel

If you have an allergy to the dye (also called contrast agent) used during the procedure and the physician decides that pre-medication prior to stent placement is not possible.
• unnatural connection between vein and artery (arterio-venous fistula)
• vessel trauma requiring surgical repair or reintervention
• worsening of heart and lung function

Potential adverse events related to the drug paclitaxel (based on studies of patients who used the drug for a prolonged period of time) or the polymer include:

• abnormal liver values
• allergic or immunologic reaction to the drug (paclitaxel)
• allergic reaction to the polymer [Translute™: poly(styrene-b-isobutylene-b-styrene)] or polymers with similar chemical structures
• anemia
• blood transfusion
• changes in blood profile (decrease of white and red blood cells and platelets)
• changes of the tissue in the vessel wall including inflammation, cell injury and cell death
• disturbances of the gastrointestinal (GI) tract and stomach
• loss of hair
• muscle pain/joint pain
• nerve disease in arms and legs

There may be other potential adverse events that are unforeseen at this time.

Exposure to paclitaxel and the polymer coating is directly related to the number of implanted stents. Use of more than one TAXUS® Stent has not been adequately evaluated. Use of multiple stents will result in your exposure to a larger amount of paclitaxel and polymer coating than experienced in the clinical studies.

There is no clinical experience on the performance of the TAXUS Stent before or after use of brachytherapy, or when used with other types of coated or drug-eluting stents.
The safety and effectiveness of the TAXUS® Express® Stent was compared to the Express Stent (an uncoated stent) in the TAXUS IV clinical trial that included 1,314 patients with a planned five-year clinical follow-up. The study results showed that patients who received a TAXUS Express Stent had a significantly lower incidence of bypass surgery or repeat angioplasty in the artery where the stent was placed, when compared to patients who received an uncoated Express Stent (4.7% vs. 12% at 9 months, 16% vs. 26% at four years). The combined occurrence of Major Adverse Cardiac Events, which is comprised of death, heart attacks, bypass surgery and repeat angioplasty, was 8.5% vs. 15% at 9 months and 22.1% vs. 31.5% at four years.

The safety and effectiveness of the TAXUS® Liberté® Stent was compared to case-matched historical control data for the TAXUS Express Stent, in the TAXUS ATLAS clinical study that included 871 patients with a planned five-year clinical follow-up. The study results showed that patients who received a TAXUS Liberté Stent had a similar incidence of bypass surgery or repeat angioplasty in the artery where the stent was placed, when compared to patients who received a TAXUS Express Stent (8.0% vs. 7.1% at 9 months). The combined occurrence of Major Adverse Cardiac Events, which is comprised of death, heart attacks, bypass surgery and repeat angioplasty, was 11% vs. 10.5% at 9 months.

Full study results are provided in the device’s Directions for Use which can be found on www.bostonscientific.com.

**Alternative Practices and Procedures**
Treatment of patients with coronary artery disease including in-stent restenosis may include exercise, diet, drug therapy, percutaneous coronary interventions (such as angioplasty, bare metal stents, coated stents and other drug-eluting stents) and coronary artery bypass surgery.
The Angioplasty Procedure

Preparation for the Procedure
Your doctor will instruct you on how to prepare for the angioplasty procedure and stent implantation procedure prior to being admitted to the hospital. Your doctor may ask you to take aspirin and other prescribed medications for several days before the procedure. This is done to “thin” the blood to prevent blood clots from forming during the procedure. It is important to tell your doctor if you cannot take aspirin or have a history of bleeding problems. Your doctor also needs to know if you are taking any other medications, have drug allergies, or are allergic to any metals or plastics.

Angioplasty and Stent Placement Procedure
Your angioplasty procedure will be performed in a specially equipped area of the hospital called the Cardiac Catheterization Laboratory. You will have to lie flat on your back during the procedure and you will remain awake, allowing you to follow your cardiologist’s instructions (e.g., “breathe deeply”). Your groin or arm will be shaved and cleaned with antiseptic and you will be given a local anesthetic to numb the area.

Your cardiologist will place an introducer sheath either in your groin or in your arm to gain access to the artery. The sheath enables the cardiologist to slide a small guiding catheter up to the entrance of the coronary artery. Through the guiding catheter, a contrast dye will be injected that helps the doctor see the coronary arteries on the X-ray machine. A finer guide wire is then advanced through the guiding catheter to the stenosis, or blockage, in the diseased artery. This provides the “railway track” which carries all the equipment necessary for the procedure.

Using the guiding catheter, a balloon catheter is then positioned precisely in the clogged area of the coronary artery. Once in place, the balloon is inflated, compressing the plaque buildup and widening the artery. At this time you may experience some chest pain. Although this is normal, let your doctor know if you are experiencing any pain.

After the artery has been widened, your doctor will then pass the stent, mounted on a delivery catheter, into the coronary artery where
the balloon was inflated. Your doctor will again inflate the balloon
to expand the stent and deliver it to the inner wall of the artery. The
stent will expand to shape itself to the size and contours of your artery.

Your doctor may choose to expand the stent further by using another
balloon. If required, the balloon catheter is inserted inside the stent
and then inflated to help the stent make better contact with the artery
wall. This part of the procedure is called *post-dilatation*. Post-dilatation
is done to enable full contact of the stent to the artery wall. Once
in place, the TAXUS® Stent will remain as a permanent implant in
your artery. The TAXUS Stent uses a very small but effective dose of
paclitaxel, which is released slowly over the time period when restenosis
is most likely to occur. Some paclitaxel will remain in the stent, with
no additional measurable amount being released into the body.

**Post-Treatment**

*After the Procedure*

After the stent is implanted, you will be moved to a cardiology ward
for a short period where you can be monitored closely as you begin
to recover. On average, your hospital stay may last one to three days
before you are discharged.

**Activity**

- Follow your doctor’s guidelines.
- Return to normal activities gradually, pacing your return to activity
  as you feel better. Check with your doctor about strenuous activities.
- Let your doctor know about any changes in lifestyle you make
during your recovery period.
- Report side effects from medications immediately. These may
  include headaches, nausea, vomiting or rash.
- Do not stop taking your medications unless you are asked to stop
  by the doctor who implanted your stent.
- Keep all follow-up appointments, including laboratory blood testing.
- Carry your Patient Information Card (provided in the back of this
  booklet) at all times. If you receive dental or medical care or report
to an emergency room/center, show your Patient Identification Card.
Medications
Your cardiologist may prescribe a number of medications to thin the blood and prevent blood clots from forming and adhering to the surface of the stent. These medications will include aspirin and blood thinning drugs such as clopidogrel (Plavix®) or ticlopidine (Ticlid®). It is extremely important to follow your medication regimen. If you stop taking these medications before being instructed to do so by your cardiologist, the chances of blood clot formation on the stent, subsequent heart attack or even death are increased.

If you plan to have any type of surgery or dental work which may require you to stop taking these medications prematurely, you and your cardiologist should discuss whether or not placement of a drug-eluting stent is the right treatment choice for you.

If surgery or dental work which would require you to stop taking these medications prematurely is recommended after you’ve received the stent, you and your doctors should carefully consider the risks and benefits of this additional surgery versus the possible risks from early discontinuation of these medications.

If you do require premature discontinuation of these medications because of significant bleeding, then your cardiologist will be carefully monitoring you for possible complications. Once your condition has stabilized, your cardiologist will possibly put you back on these medications.

Follow-Up Examinations
You will need to see the doctor who implanted your stent for routine follow-up examinations. During these visits, your doctor will monitor your progress and evaluate your medications, the clinical status of your coronary artery disease, and how the stent is working for you.
**FREQUENTLY ASKED QUESTIONS**

**Can I undergo MRI or scanner testing with a stent?**
MRI safety testing has shown that the TAXUS® Liberté® Stent is MR Conditional and that a patient with a TAXUS Liberté Stent may safely undergo an MRI scan under certain conditions listed on the stent implant card. Prior to undergoing an MRI scan, inform your doctor or MR technologist that you have a TAXUS Liberté Stent.

**Can the stent move or rust?**
Once positioned by your physician, the stent does not move on its own. It is manufactured so it will not rust.

**Can I walk through metal detectors with a stent?**
Yes, without any fear of setting them off.

**How soon can I go back to work?**
The majority of people return to work within a few days following the procedure.

**What if I still get pains?**
If you experience pain, immediately inform your cardiologist or the center where the procedure was performed.

**Can I play sports?**
Yes, but be cautious! Your doctor will tell you what sports you can play and when you can start them.

**What should I change in my diet?**
Your doctor may prescribe a low-fat, low-cholesterol diet to help reduce the levels of fat in your blood and reduce your risk.

**Does paclitaxel have any drug interactions that I should be concerned about?**
Formal drug interaction studies with paclitaxel after use of a TAXUS Stent have not been conducted. Since some paclitaxel will remain on the stent, interactions at the location of the stent itself affecting the performance of the drug cannot be ruled out. Be sure to discuss with your doctor any drugs you are taking or planning to take.

**What if I have taken paclitaxel before for cancer treatment and had a reaction to it?**
Be sure to let your doctor know if you have had a previous allergic reaction to paclitaxel.

**GLOSSARY**

**Angina Pectoris** Symptoms experienced when the heart muscle is not receiving adequate oxygen (may include chest, arm, jaw or back pain, shortness of breath, nausea, vomiting).

**Angiogram** X-ray of the heart using contrast dye injection.

**Angioplasty** A minimally invasive treatment to open blocked coronary arteries. Also known as percutaneous transluminal coronary angioplasty (PTCA).

**Atherosclerosis** A disease in which the flow of blood to the heart is restricted with plaque deposits and, therefore, less oxygen and other nutrients reach the heart muscle. This may lead to chest pain (angina pectoris) or to a heart attack (myocardial infarction).

**Balloon Angioplasty** Opening the blocked artery by using a balloon catheter that is inflated inside the artery.

**Brachytherapy** The use of a locally delivered dose of radiation to control the process of restenosis.
**Catheter** A small, thin plastic tube used to provide access to parts of the body, such as the coronary arteries.

**Coronary Angiogram** A test in which contrast dye is injected into the coronary arteries and allows the doctor to see the arteries on an X-ray machine.

**Coronary Arteries** The arteries that surround the heart and supply blood containing oxygen and nutrients to the heart muscle.

**Coronary Artery Bypass Graft Surgery (CABG)** Open heart or bypass surgery.

**Coronary Artery Disease (CAD)** Disease affecting the coronary arteries that surround the heart and supply blood to the heart muscle. CAD occurs when the lumen of the coronary arteries becomes narrowed with plaque deposits (a buildup of cholesterol and other fats, calcium and elements carried in the blood).

**Electrocardiogram (ECG/EKG)** A test that records changes in the electrical activity of the heart.

**Plaque** Accumulation or buildup of cholesterol, fatty deposits, calcium and collagen in a coronary vessel that leads to blockages in the blood vessel.

**Post-Dilatation** After the stent has been expanded, another balloon catheter may be inserted inside the stent and inflated to size the stent more precisely to the wall.

**Restenosis** Recurrent blockage or narrowing of a previously treated vessel.

**Stent** An expandable metal tubular structure (lattice) that supports the vessel wall and maintains blood flow through the opened vessel.

**Surgery** See Angioplasty.

**Stress Test** A test that records the heart’s electrical activity while the patient exercises. May show whether parts of the heart muscle have been damaged due to insufficient oxygen flow to the heart.

**Vessel Recoil** When an artery is stretched during an angioplasty procedure, the elastic properties of the coronary vessel wall may cause the vessel to “shrink back” after the procedure.

**In-Stent Restenosis** Recurrent blockage or narrowing of a previously stented vessel.

**Introducer Sheath** A tube that is inserted into the body to provide an access point and allow the insertion of other instruments into the artery.

**Lumen** The inner channel of a vessel.

**Magnetic Resonance Imaging (MRI)** A non-invasive way to take pictures of the body. MRI uses powerful magnets and radio waves, unlike x-rays and computed tomographic (CT) scans which use radiation.

**Myocardial Infarction** Permanent damage to the heart tissue and muscle due to the interruption of the blood supply to the area. Commonly referred to as a heart attack.

**Percutaneous Transluminal Coronary Angioplasty (PTCA)** See Angioplasty.
If you require a magnetic resonance imaging (MRI) scan, tell your doctor or MRI technician that you have a stent implant. Through non-clinical testing, the TAXUS Liberté Stent, in single and in overlapped configurations up to 60 mm in length, has been shown to be MR Conditional (poses no known hazards under specified conditions). The conditions are as follows:

- Field strengths of 3 Tesla and 1.5 Tesla
- Static magnetic field gradient < 16 T/m (extrapolated)
- Normal operating mode (maximum whole body averaged specific absorption rate (SAR) of 2.0 W/kg) for a total active MR scan time (with RF exposure) of 15 minutes or less
- Field strengths of 3 Tesla and 1.5 Tesla
- Static magnetic field gradient < 16 T/m (extrapolated)

The stent(s) should not migrate in this MRI environment, and MRI may be performed immediately following the implantation of a TAXUS Liberté Stent(s). Prior to undergoing an MRI scan, inform your doctor that you have a TAXUS Liberté Stent.

Your cardiologist has prescribed a number of medications to thin the blood and prevent blood clots after your implant. It is extremely important to follow the medication regimen as prescribed by your cardiologist. Before considering any surgery or dental work which would require you to stop taking these medicines early, you and your doctors should consider the risks from stopping the medicine(s). If necessary, consult with your cardiologist before taking any new medications. Your cardiologist has prescribed a number of medications to thin the blood and prevent blood clots after your implant.

Stent Identification Information

- Patient Name
- Implanting Physician’s Name
- Date of Implant
- Stent Material
- Patient Phone Number
- Product Name
- Product Lot Number
- Stent Location
- Physician’s Phone Number

PLEASE CARRY YOUR CARD AT ALL TIMES.

If you require a magnetic resonance imaging (MRI) scan, tell your doctor or MRI technician that you have a TAXUS Liberté Stent.
Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each product. CAUTION: Federal (U.S.A.) law and governing law outside the U.S.A. restricts these products to sale by or on the order of a physician. TAXUS® Stents are a product of Boston Scientific Corporation.

© 2010 Boston Scientific Corporation or its affiliates. All rights reserved. Printed in U.S.A.